We currently have three clinical candidates, filed our first IND in 2Q06 (KD3010), and anticipate subsequent IND filings in 4Q06 (KD7040) and 3Q07 (KD5170).
KD3010, is a PPARδ selective agonist that is currently being clinically evaluated for its ability to address the underlying causes of metabolic syndrome. More >
KD7040, is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. More >
KD5170, is a histone deacetylase (HDAC) inhibitor for treatment of hematological and solid tumors. More >
